Multiple Sclerosis
Item
ms patients diagnosed with clinically definite ms according to the mcdonald criteria (polman et al., 2005)
boolean
C0026769 (UMLS CUI [1])
glatiramer acetate
Item
starting ga monotherapy (20mg/day sc) at the time of the oct scan
boolean
C0289884 (UMLS CUI [1])
Retinal nerve fiber layer Thickness OCT | Volume macular total OCT
Item
having baseline clinical oct scan that included rnflt and tmv assessment at the start of the ga
boolean
C1517753 (UMLS CUI [1,1])
C1280412 (UMLS CUI [1,2])
C0920367 (UMLS CUI [1,3])
C0449468 (UMLS CUI [2,1])
C0332574 (UMLS CUI [2,2])
C0439810 (UMLS CUI [2,3])
C0920367 (UMLS CUI [2,4])
Retinal nerve fiber layer Thickness OCT | Volume macular total OCT | Healthy Control
Item
having baseline clinical oct scan that included rnflt and tmv assessment (healthy controls)
boolean
C1517753 (UMLS CUI [1,1])
C1280412 (UMLS CUI [1,2])
C0920367 (UMLS CUI [1,3])
C0449468 (UMLS CUI [2,1])
C0332574 (UMLS CUI [2,2])
C0439810 (UMLS CUI [2,3])
C0920367 (UMLS CUI [2,4])
C2986479 (UMLS CUI [3])
Multiple Sclerosis, Relapsing-Remitting
Item
ms patients having a rr disease course (lublin and reingold, 1996)
boolean
C0751967 (UMLS CUI [1])
Age
Item
age 18-65 (healthy controls will be matched to ms patients for age and sex)
boolean
C0001779 (UMLS CUI [1])
Informed Consent
Item
signed informed consent at the 24-month follow-up
boolean
C0021430 (UMLS CUI [1])
Exclusion Criteria None
Item
none of the exclusion criteria
boolean
C0680251 (UMLS CUI [1,1])
C0549184 (UMLS CUI [1,2])
Recurrent disease
Item
patients who had a relapse within 30 days prior to oct scan date
boolean
C0277556 (UMLS CUI [1])
Steroid therapy
Item
patients who received steroid treatment within 30 days prior to oct scan date
boolean
C0149783 (UMLS CUI [1])
Pregnancy | Breast Feeding | Childbearing Potential Contraceptive methods Unwilling
Item
women who are pregnant, lactating or of childbearing age who do not consent to approved contraceptive use during the study
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C3831118 (UMLS CUI [3,1])
C0700589 (UMLS CUI [3,2])
C0558080 (UMLS CUI [3,3])
Immunomodulation Multiple Sclerosis | Immunosuppressant drug therapy Multiple Sclerosis | Exception Glatiramer acetate | Interferon-beta | Mitoxantrone | Cyclophosphamide | Cladribine | fludarabine | Cyclosporine | Whole-Body Irradiation | Azathioprine | Methotrexate | Immunoglobulins, Intravenous | Cellcept | natalizumab
Item
ms patients who used other imunomodulatory or immunosuppressant treatment other than ga during the follow-up (e.g., ifn-β, mitoxantrone, cyclophosphamide, cladribine, fludarabine, cyclosporine, total body, azathioprine, methotrexate, ivig, cellcept, natalizumab, etc.)
boolean
C1963758 (UMLS CUI [1,1])
C0026769 (UMLS CUI [1,2])
C1096650 (UMLS CUI [2,1])
C0026769 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0289884 (UMLS CUI [3,2])
C0015980 (UMLS CUI [4])
C0026259 (UMLS CUI [5])
C0010583 (UMLS CUI [6])
C0092801 (UMLS CUI [7])
C0059985 (UMLS CUI [8])
C0010592 (UMLS CUI [9])
C0043162 (UMLS CUI [10])
C0004482 (UMLS CUI [11])
C0025677 (UMLS CUI [12])
C0085297 (UMLS CUI [13])
C0592558 (UMLS CUI [14])
C1172734 (UMLS CUI [15])